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Stem cells in prostate regeneration and cancer
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Understanding the lineage relationship between normal progeni-
tor cells and cell type(s) of origin for cancer may yield important
molecular insights into prostate cancer prognosis and treatment
response. For example, several studies have suggested that the
prostate basal epithelial compartment contains stem/progenitor cells
that can be transformed to initiate cancers in tissue reconstitution
assays. In our work, we have shown that a known regulator of
prostate epithelial differentiation, the homeobox gene Nkx3.1, marks
a luminal stem cell population that functions during prostate
regeneration. Genetic lineage-tracing studies demonstrate that rare
cells which express Nkx3.1 in the absence of testicular androgens
(castration-resistant Nkx3.1-expressing cells, CARNs) are bipotential
and can self-renew in vivo, while single-cell transplantation assays
show that CARNs can reconstitute prostate ducts in renal grafts.
Targeted deletion of the Pten tumor suppressor gene in CARNs results
in rapid formation of carcinoma following androgen-mediated
regeneration. These observations indicate that CARNs represent a
novel luminal stem cell population that is an efficient target for
oncogenic transformation in prostate cancer. In our ongoing work, we
are investigating the properties of CARNs as well as other epithelial
cell types during prostate regeneration and as cells of origin for
cancer in vivo. In particular, we have utilized CK5-CreERT2 transgenic
mice for lineage-tracing of basal cells during androgen-mediated
prostate regeneration and oncogenic transformation. We will present
our recent findings and discuss their implications with respect to
elucidating the prostate epithelial lineage hierarchy and its relation-
ship to cancer initiation.
doi:10.1016/j.ydbio.2011.05.063
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Hectd1 regulates intracellular trafficking of Hsp90 to control its
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In addition to its well-known role as a cellular chaperone, secreted
Hsp90 controls cell motility. However, the pathways that regulate
Hsp90 secretion remain largely unknown. Here we establish that the
previously uncharacterized E3 ubiquitin ligase Hectd1 regulates
secretion of Hsp90. Homozygous Hectd1 mutant mouse embryos
exhibit exencephaly, a type of neural tube defect that arises when the
anterior neural tube fails to close completely during embryonic
development. Exencephaly in Hectd1 mutants is associated with
disorganized and highly motile cranial mesenchyme. Our data
demonstrates in vivo that Hectd1-dependent K63-linked polyubiqui-
tination of Hsp90 regulates its secretion. In mutant cranial mesench-
yme cells, both secretion of Hsp90 and cell migration is enhanced.
Importantly, we show that this enhanced migration is highly
dependent on the excess Hsp90 secreted from mutant cells. Together
our data set forth a model where increased secretion of Hsp90 in the
cranial mesenchyme of Hectd1 mutant embryos is responsible, at
least in part, for the altered organization and migration of these cells
and provides a potential molecular mechanism underlying the neural
tube defect.
doi:10.1016/j.ydbio.2011.05.064
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Craniofrontonasal syndrome (CFNS) is a congenital condition
comprising multiple craniofacial developmental anomalies, including
cleft palate, and is caused by mutations in the X-linked EPHRIN-B1
(EFNB1) gene. Interestingly, females harboring heterozygous muta-
tion of EFNB1are more severely affected than hemizygous males, a
mysterious characteristic that is mirrored in mice with targeted null
mutation of efnb1. Efnb1 encodes a trans-membrane molecule that
can act by multiple distinct biochemical mechanisms either as a
ligand or a receptor to mediate cell-cell signaling. We have previously
shown that ephrin-B1 contributes to craniofacial development as a
ligand activating EphB receptor tyrosine kinase signaling. Here, we
show that ephrin-B1 promotes cell proliferation in the palatal
mesenchyme to drive outgrowth of the palatal shelves and control
their shape. Due to random X-inactivation, efnb1+/− heterozygotes
display mosaic disruption of ephrin-B1 expression domains. We find
that this mosaic disruption of ephrin-B1 expression boundaries leads
to a mosaic disruption of cell proliferation rate that correlates with
the more severe dysmorphogenesis of efnb1+/− heterozygotes that
is a hallmark of CFNS. Finally, we have identified the extracellular
signaling regulated kinase/mitogen activated protein kinase (ERK/
MAPK) signal transduction pathway as a key mediator of ephrin-B1-
driven morphogenesis. These findings provide mechanistic insight
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into the role of ephrin-B1 in craniofacial development and CFNS
pathogenesis.
doi:10.1016/j.ydbio.2011.05.065
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My laboratory has utilized Drosophila to address specific aspects of
epithelial development and disease with a recent focus on cancer and
diabetes. Our emphasis has been on in situ exploration of cellular
phenomenon. To this end, we have developed several approaches
including live visualization, cell ablation, computational modeling,
and high throughput drug screening protocols. My laboratory's
collaboration with clinicians and AstraZeneca helped bring Vandeta-
nib to market for Medullary Thyroid Carcinoma. Our cancer genetic
models are established based directly on human sequencing data and
emphasize genetic complexity: we have developed multi-hit cancer
models for breast, lung, and colorectal tumors. We have utilized these
models to develop systems approaches towards understanding and
addressing cancer metastasis and cancer metabolism. Through this
work we have developed novel models for metastasis and for cancer
metabolism. In addition, we have performed genetic and drug screens
that have resulted in novel genes and drugs, and we are working to
bring these compounds to the clinics. Working closely with medicinal
chemists including Kevan Shokat, we have combined genetics and
chemistry in a unique approach to developing polypharmacological
agents as well as improving clinically relevant compounds. Regarding
diabetes, we have established a Type 2 diabetes mellitus (T2DM)
model. We are exploring the links between T2DM and obesity,
hyperglycemia, hyperinsulinemia, hyperlipidemia, cardiomyopathy,
and nephropathy. In collaboration with Thomas Baranski we have
developed novel models for the link between obesity and diabetes
and for loss of podocyte function in diabetic nephropathy. In addition,
we are completing a collaboration with Francis Collins and colleagues
that utilizes Drosophila as a tool for exploring GWAS studies; we have
used this approach to identify novel loci linked to heightened risk for
diabetes.
doi:10.1016/j.ydbio.2011.05.066
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Autism spectrum disorders (ASD) are prevalent developmental
disorders, diagnosed in approximately 1% of children. Hemizygosity
of the human 16p11.2 interval, a region containing 25 genes, is highly
associated with ASD. This finding implies that within this interval,
one (or more) gene acts as a dosage sensor, and, when present in one
copy, is associated with development of ASD. We are using the
zebrafish to dissect the activity and dosage sensitivity of 16p11.2
homologs during brain development. Since zebrafish do not display
the complex human behaviors associated with autism, this system is
not a direct phenotypic model of the human disorder. Rather, we
define the fish as a “tool”which allows insight into gene function and
associated pathways, by using rapid assays and screens for chemicals
which modulate gene function that are not possible in mammalian
systems (Sive, Dis Model Mech 4:137-8 (2011)). We identified
zebrafish homologs for 20/25 genes in the 16p11.2 region, and
assayed their function using a grid of eleven phenotypic assays. Our
data show that this region is very active, such that 19/20 genes tested
in loss of function assays give abnormal phenotypes, altering brain
morphology, axon outgrowth, touch response, movement and somite
or tail morphology. To date, 16 have been rescued by human mRNA
expression, confirming orthology of human and fish genes. Quanti-
tative RNA analyses have identified the AldolaseA gene as a potential
hemizygosity sensor, since a decrease of 50% in RNA levels gives a
strong brain phenotype. These data demonstrate that most genes
within the 16p11.2 region are active during brain development, and
may include a pivotal sensor for gene copy number associated with
autism.
doi:10.1016/j.ydbio.2011.05.067
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Type 2 Diabetes (T2D) is a prevalent metabolic disorder associated
with pancreatic ß-cell failure and complex polygenic etiologies.
Genome wide association studies (GWAS) have implicated many
genes, including HNF1B and WNT2B in T2D susceptibility. Further,
heterozygous mutations in HNF1B can cause a form of monogenic
diabetes called Maturity Onset Diabetes of the Young 5 (MODY5). The
roles of these genes in pancreas development and diabetes remain
elusive. We report a novel hypomorphic hnf1b mutation in zebrafish
that causes MODY5-like phenotypes, islet disorganization and
variable pancreas agenesis/hypoplasia, revealing that hnf1b plays a
essential role in pancreas specification and morphogenesis, distinct
from its function in endoderm regionalization and liver specification.
Using this allele, we uncover a critical role for hnf1b in regulating ß-
cell numbers and find that hnf1b/wnt2bb double mutants are
synthetic lethal and exhibit a specific loss of hepatopancreatic
progenitors. Our data supports a model whereby hnf1b functions to
generate a permissive domain in the foregut endoderm for Wnt
signaling to induce expression of T2D genes, hhex and prox1, and
hepatopancreatic fate. Collectively, our findings provide a new model
for MODY5, yield insight into the etiology of HNF1B diabetes, suggest
a new mechanism for hepatopancreatic specification, and establish
genetic interactions among genes associated with T2D.
doi:10.1016/j.ydbio.2011.05.068
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